PLL Therapeutics’ polypeptide delivery platform for restoring gut integrity combines early-stage diagnostics and therapeutics to treat the root cause of autoimmune, neurodegenerative (ALS) and proliferative disorders.
Polypeptide delivery platform: way of transporting active substances to the point of use. Read more …
Diagnostics service: Early-stage and companion diagnostics. Read more …
Clinical trials: Treating patients by addressing dysbiosis – an imbalance of the gut microbiota – to tackle the root cause of chronic and degenerative diseases. Read more …
CEO, Co-Founder & shareholder
Chairman of the Board, Co-Founder & shareholder
Co-Founder & shareholder
Board member & shareholder
Chief Operating Officer
Exclusive interview in Pharmaceutiques with Jean Pascal Zambaux, CEO, who explains how PLL Therapeutics is revolutionizing ALS care with an early-stage blood test (92% sensitivity) to detect the disease before symptoms appear, and a therapy targeting dysbiosis via the gut-brain axis. The challenge: to intervene before 70% of motor neurons are destroyed....
Stage one results from PLL Therapeutics’ first-in-human, multi-stage phase I/II trial show favorable safety and tolerability of PLL001 in 12 ALS patients. Australian multi-stage study tested single ascending subcutaneous doses of PLL001 – in three dose cohorts - with placebo control....
Expansion in Asia-Pacific with second subsidiary, following Australia, pivotal to enrolling patients in phase II trial targeting ALS, a motor neuron disease with no cure....
Talk will highlight for investors role of PLL Therapeutics’ poly-L-Lysine-based therapy in helping combat neurodegenerative disorders and in early-stage and companion biomarkers....
Preeminent researcher in Amyotropic Lateral Sclerosis (ALS), Dr. Corcia heightens expertise behind PLL Therapeutics’ polypeptide delivery platform and development of world’s first blood biomarker to detect early onset of ALS...
Multi-stage Australian study will evaluate safety of PLL001 in 12 ALS patients, testing three different doses along with placebo...
Australia’s Human Research Ethics Committees (HREC) cleared first-in-human study of drug candidate PLL001. PLL001 aims at restoring microbiome and stopping gut from leaking to treat root cause of ALS, not solely symptoms...
The intestine is well known to be our second brain and nearly 500 million neurons line our intestine (20 times less than our brain). But in the history of humanity was not the intestine our first Brain? The first primitive organisms were a simple digestive tract!...
The safety of PLL001 was evaluated in vivo in SOD1 mice treated or. This study was carried out in 60 mice split 4 groups (WT vehicle group1, SOD1 vehicle group 2, SOD1 Low Dose group 3 and SOD1 High Dose group 4). The low dose was estimated to be equivalent of the foreseen clinical dose and the high dose was 10 folds higher....
More and more the Gut is highlighted in many diseases as playing a key role in Parkinson or ALS by being the open gate for many components as bacteria, fungal element, lipopolysaccharides (LPS), toxins and chemicals to move in the blood and in the brain which can have a role in the development of the disease and in its chronicity....